AACR Cancer Progress Report 2019: References

References 1-50

1. Arteaga CL, Adamson PC, Engelman JA, Foti M, Gaynor RB, Hilsenbeck SG, et al. AACR Cancer Progress Report 2014. Clin Cancer Res [Internet]. 2014;20:S1 LP-S112. Available from: http://clincancerres.aacrjournals.org/content/20/19_Supplement/S1.abstract
2. America Cancer Society. Facts & Figures 2019. Am Cancer Soc Atlanta, Ga. 2019;
3. Miller D, Nogueira L, Mariotto AB, Rowland JH, Yabroff KR, Alfano CM, et al. Cancer treatment and survivorship statistics, 2019. CA Cancer J Clin [Internet]. American Cancer Society; 2019 [cited 2019 Jun 19];caac.21565. Available from: https://onlinelibrary.wiley.com/doi/abs/10.3322/caac.21565
4. American Cancer Society. Cancer Treatment & Survivorship Facts & Figures 2016-2017.
5. Section S, Epidemic TO. Global Cancer Facts & Figures 4th Edition. 2018;
6. Lancet T. Making cancer data count. Lancet [Internet]. Elsevier; 2014;383:1946. Available from: http://dx.doi.org/10.1016/S0140-6736(14)60939-9
7. cancerprogressreport.org [Internet]. Philadelphia: American Association for Cancer Research; ©2018 [cited year month date]. Available from http://www.cancerprogressreport.org/ . 2018;
8. Howlader N, Noone AM, Krapcho M, Miller D, Brest A, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ CK (eds). SEER Cancer Statistics Review, 1975-2016, National Cancer Institute. Bethesda, MD, https://seer.cancer.gov/csr/1975_2016/, based on November 2018 SEER data submission, posted to the SEER web site, April 2019. [cited 2019 Jun 19]; Available from: https://seer.cancer.gov/csr/1975_2016/sections.html
9. National Cancer Institute. Cancer Health Disparities Definitions – National Cancer Institute [Internet]. [cited 2019 Jun 19]. Available from: https://www.cancer.gov/about-nci/organization/crchd/about-health-disparities/definitions#general
10. Siegel RL, Miller KD. Cancer Statistics , 2019. 2019;69:7–34.
11. Bhatia S, Landier W, Shangguan M, Hageman L, Schaible AN, Carter AR, et al. Nonadherence to oral mercaptopurine and risk of relapse in Hispanic and non-Hispanic white children with acute lymphoblastic leukemia: a report from the children’s oncology group. J Clin Oncol [Internet]. American Society of Clinical Oncology; 2012 [cited 2019 Jul 14];30:2094–101. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22564992
12. Shah NN, Xi Y, Liu Y, Koff JL, Flowers CR, Behera M, et al. Racial and Socioeconomic Disparities in Mantle Cell Lymphoma. Clin Lymphoma Myeloma Leuk [Internet]. 2019 [cited 2019 Jun 19]; Available from: https://linkinghub.elsevier.com/retrieve/pii/S2152265018317208
13. Gonzales G, Zinone R. Cancer diagnoses among lesbian, gay, and bisexual adults: Results from the 2013–2016 National Health Interview Survey. Cancer Causes Control [Internet]. 2018 [cited 2019 Jun 19];29:845–54. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30043193
14. DeSantis CE, Miller KD, Goding Sauer A, Jemal A, Siegel RL. Cancer Statistics for African Americans, 2019. CA Cancer J Clin [Internet]. 2019 [cited 2019 Feb 15]; Available from: http://www.ncbi.nlm.nih.gov/pubmed/30762872
15. AACR Cancer Progress Report 2017 [Internet]. Philadelphia; 2017. Available from: https://cancerprogressreport.org
16. Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2018). Global Cancer Observatory: Cancer Tomorrow. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.fr/tomorrow, accessed [DD Month YYYY]. [Internet]. [cited 2019 Jul 29]. Available from: https://www.iarc.fr/
17. 2017 National Population Projections Datasets [Internet]. U.S. Census Bur. Washingt. DC. 2017. Available from: https://www.census.gov/data/datasets/2017/demo/popproj/2017-popproj.html
18. Wang TW, Asman K, Gentzke AS, Cullen KA, Holder-Hayes E, Reyes-Guzman C, et al. Tobacco Product Use Among Adults — United States, 2017. MMWR Morb Mortal Wkly Rep [Internet]. 2018;67:1225–32. Available from: http://www.cdc.gov/mmwr/volumes/67/wr/mm6744a2.htm?s_cid=mm6744a2_w
19. Islami F, Goding Sauer A, Gapstur SM, Jemal A. Proportion of Cancer Cases Attributable to Excess Body Weight by US State, 2011-2015. JAMA Oncol [Internet]. American Medical Association; 2019 [cited 2019 Mar 22];5:384. Available from: http://oncology.jamanetwork.com/article.aspx?doi=10.1001/jamaoncol.2018.5639
20. Wilson BE, Jacob S, Yap ML, Ferlay J, Bray F, Barton MB. Estimates of global chemotherapy demands and corresponding physician workforce requirements for 2018 and 2040: A population-based study. Lancet Oncol [Internet]. Elsevier; 2019 [cited 2019 Jun 19];20:769–80. Available from: http://www.ncbi.nlm.nih.gov/pubmed/31078462
21. Leach CR, Weaver KE, Aziz NM, Alfano CM, Bellizzi KM, Kent EE, et al. The complex health profile of long-term cancer survivors: Prevalence and predictors of comorbid conditions. J Cancer Surviv [Internet]. 2015 [cited 2019 Jun 19];9:239–51. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25319681
22. Bhakta N, Liu Q, Ness KK, Baassiri M, Eissa H, Yeo F, et al. The cumulative burden of surviving childhood cancer: An initial report from the St Jude Lifetime Cohort Study (SJLIFE). Lancet (London, England). England; 2017;390:2569–82.
23. Bluethmann SM, Mariotto AB, Rowland JH. Anticipating the “Silver Tsunami”: Prevalence Trajectories and Comorbidity Burden among Older Cancer Survivors in the United States. Cancer Epidemiol Biomarkers & Prev [Internet]. 2016;25:1029 LP – 1036. Available from: http://cebp.aacrjournals.org/content/25/7/1029.abstract
24. Mayer DK, Alfano CM. Personalized Risk-Stratified Cancer Follow-Up Care: Its Potential for Healthier Survivors, Happier Clinicians, and Lower Costs. JNCI J Natl Cancer Inst [Internet]. Narnia; 2019 [cited 2019 Jun 19];111:442–8. Available from: https://academic.oup.com/jnci/article/111/5/442/5307983
25. Union for International Cancer Control. The Economics of Cancer Prevention and Control. Data Digest. [Internet]. 2014. Available from: http://issuu.com/uicc.org/docs/wcls2014_economics_of_cancer_final?e=10430107/10454633
26. Islami F, Miller KD, Siegel RL, Zheng Z, Zhao J, Han X, et al. National and State Estimates of Lost Earnings From Cancer Deaths in the United States. JAMA Oncol [Internet]. 2019 [cited 2019 Jul 14]; Available from: http://www.ncbi.nlm.nih.gov/pubmed/31268465
27. Collins FS, Anderson JM, Austin CP, James F, Birnbaum LS, Briggs P, et al. Basic science : Bedrock of progress Join the. Science (80- ). 2016;351:1405.
28. Galkina Cleary E, Beierlein JM, Khanuja NS, McNamee LM, Ledley FD. Contribution of NIH funding to new drug approvals 2010–2016. Proc Natl Acad Sci. 2018;115:201715368.
29. Kucab JE, Zou X, Morganella S, Joel M, Nanda AS, Nagy E, et al. A Compendium of Mutational Signatures of Environmental Agents. Cell [Internet]. Cell Press; 2019 [cited 2019 Jun 19];177:821-836.e16. Available from: https://www.sciencedirect.com/science/article/pii/S0092867419302636?via%3Dihub
30. Hutter C, Zenklusen JC. The Cancer Genome Atlas: Creating Lasting Value beyond Its Data. Cell [Internet]. Elsevier; 2018 [cited 2019 Jun 19];173:283–5. Available from: https://www.cell.com/cell/fulltext/S0092-8674(18)30374-X?utm_campaign=STMJ_1522958526_SC&utm_channel=WEB&utm_source=WEB&dgcid=STMJ_1522958526_SC
31. Gröbner SN, Worst BC, Weischenfeldt J, Buchhalter I, Kleinheinz K, Rudneva VA, et al. The landscape of genomic alterations across childhood cancers. Nature [Internet]. 2018 [cited 2018 May 4];555:321–7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29489754
32. Ma X, Liu Y, Liu Y, Alexandrov LB, Edmonson MN, Gawad C, et al. Pan-cancer genome and transcriptome analyses of 1,699 paediatric leukaemias and solid tumours. Nature [Internet]. 2018 [cited 2018 May 4];555:371–6. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29489755
33. Susswein LR, Marshall ML, Nusbaum R, Vogel Postula KJ, Weissman SM, Yackowski L, et al. Pathogenic and likely pathogenic variant prevalence among the first 10,000 patients referred for next-generation cancer panel testing. Genet Med [Internet]. 2016 [cited 2019 Jul 9];18:823–32. Available from: http://www.nature.com/articles/gim2015166
34. Huang K-L, Mashl RJ, Wu Y, Ritter DI, Wang J, Oh C, et al. Pathogenic Germline Variants in 10,389 Adult Cancers. Cell [Internet]. 2018 [cited 2019 Jul 9];173:355-370.e14. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0092867418303635
35. Kawanishi S, Ohnishi S, Ma N, Hiraku Y, Murata M. Crosstalk between DNA Damage and Inflammation in the Multiple Steps of Carcinogenesis. Int J Mol Sci [Internet]. 2017 [cited 2018 Jun 11];18:1808. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28825631
36. Baselga J, Bhardwaj N, Cantley LC, DeMatteo R, DuBois RN, Foti M, et al. AACR Cancer Progress Report 2015. Clin. Cancer Res. United States; 2015. page S1-128.
37. Dawson MA. Therapeutic Opportunities. 2017;1:379–85.
38. Kresovich JK, Xu Z, O’Brien KM, Weinberg CR, Sandler DP, Taylor JA. Methylation-Based Biological Age and Breast Cancer Risk. JNCI J Natl Cancer Inst [Internet]. 2019 [cited 2019 Apr 22]; Available from: https://academic.oup.com/jnci/advance-article/doi/10.1093/jnci/djz020/5341521
39. Popejoy, Alice B., Fullerton SM. Genomics is falling. Nature. 2016;538:161–4.
40. Sirugo G, Williams SM, Tishkoff SA. The Missing Diversity in Human Genetic Studies. Cell [Internet]. Elsevier Inc.; 2019;177:26–31. Available from: https://doi.org/10.1016/j.cell.2019.02.048
41. Mcgranahan N, Swanton C. Review Clonal Heterogeneity and Tumor Evolution : Past , Present , and the Future. Cell [Internet]. Elsevier Inc.; 2017;168:613–28. Available from: http://dx.doi.org/10.1016/j.cell.2017.01.018
42. Hawkins ED, Duarte D, Akinduro O, Khorshed RA, Passaro D, Nowicka M, et al. T-cell acute leukaemia exhibits dynamic interactions with bone marrow microenvironments. Nature. 2016;
43. Sun Y. Tumor microenvironment and cancer therapy resistance. Cancer Lett [Internet]. Elsevier Ireland Ltd; 2016;380:205–15. Available from: http://dx.doi.org/10.1016/j.canlet.2015.07.044
44. American Association for Cancer Research. AACR Cancer Progress Report 2016. Clin Cancer Res 2016. 2016;22 (Supple.
45. Sicklick JK, Kato S, Okamura R, Schwaederle M, Hahn ME, Williams CB, et al. Molecular profiling of cancer patients enables personalized combination therapy: The I-PREDICT study. Nat Med [Internet]. Nature Publishing Group; 2019 [cited 2019 Jun 19];25:744–50. Available from: http://www.nature.com/articles/s41591-019-0407-5
46. Islami F, Sauer AG, Miller KD, Siegel RL, Fedewa SA, Jacobs EJ, et al. Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States. CA Cancer J Clin [Internet]. 2017;68:31–54. Available from: http://doi.wiley.com/10.3322/caac.21440
47. Goding Sauer A, Siegel RL, Jemal A, Fedewa SA. Current Prevalence of Major Cancer Risk Factors and Screening Test Use in the United States: Disparities by Education and Race/Ethnicity. Cancer Epidemiol Biomarkers Prev [Internet]. 2019;28:629–42. Available from: http://cebp.aacrjournals.org/lookup/doi/10.1158/1055-9965.EPI-18-1169
48. Gallaway MS, Henley SJ, Steele CB, Momin B, Thomas CC, Jamal A, et al. Surveillance for Cancers Associated with Tobacco Use — United States, 2010–2014. MMWR Surveill Summ [Internet]. 2018;67:1–42. Available from: http://www.cdc.gov/mmwr/volumes/67/ss/ss6712a1.htm?s_cid=ss6712a1_w
49. Lundeen EA, Park S, Pan L, O’Toole T, Matthews K, Blanck HM. Obesity Prevalence Among Adults Living in Metropolitan and Nonmetropolitan Counties – United States, 2016. MMWR Morb Mortal Wkly Rep [Internet]. 2018 [cited 2019 Jun 19];67:653–8. Available from: http://www.cdc.gov/mmwr/volumes/67/wr/mm6723a1.htm?s_cid=mm6723a1_w
50. Vaeth PAC, Wang-Schweig M, Caetano R. Drinking, Alcohol Use Disorder, and Treatment Access and Utilization Among U.S. Racial/Ethnic Groups. Alcohol Clin Exp Res [Internet]. NIH Public Access; 2017 [cited 2018 Jun 4];41:6–19. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28019654

References 51-100

51. Correnti CM, Klein DJ, Elliott MN, Veledar E, Saraiya M, Chien AT, et al. Racial disparities in fifth-grade sun protection: Evidence from the Healthy Passages study. Pediatr Dermatol [Internet]. 2018 [cited 2019 Jul 7];35:588–96. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29962040
52. Walker TY, Elam-Evans LD, Yankey D, Markowitz LE, Williams CL, Mbaeyi SA, et al. National, Regional, State, and Selected Local Area Vaccination Coverage Among Adolescents Aged 13–17 Years — United States, 2017. MMWR Morb Mortal Wkly Rep [Internet]. 2018;67:909–17. Available from: http://www.cdc.gov/mmwr/volumes/67/wr/mm6733a1.htm?s_cid=mm6733a1_w
53. Barrow TM, Klett H, Toth R, Böhm J, Gigic B, Habermann N, et al. Smoking is associated with hypermethylation of the APC 1A promoter in colorectal cancer: the ColoCare Study. J Pathol [Internet]. 2017 [cited 2018 Mar 15];243:366–75. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28791728
54. Vaz M, Hwang SY, Kagiampakis I, Phallen J, Patil A, O’Hagan HM, et al. Chronic Cigarette Smoke-Induced Epigenomic Changes Precede Sensitization of Bronchial Epithelial Cells to Single-Step Transformation by KRAS Mutations. Cancer Cell [Internet]. 2017 [cited 2018 Mar 15];32:360-376.e6. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28898697
55. CDC Vital Signs, November 2016. Cancer and tobacco use. CDC Vital Signs, November, 2016.
56. Benefits of Quitting | smokefree.gov [Internet]. [cited 2019 Jun 19]. Available from: https://smokefree.gov/quit-smoking/why-you-should-quit/benefits-of-quitting
57. United States Department of Health and Human Services. The Health Consequences of Smoking—50 Years of Progress A Report of the Surgeon General. A Rep Surg Gen. 2014;1081.
58. Tsai J, Homa DM, Gentzke AS, Mahoney M, Sharapova SR, Sosnoff CS, et al. Exposure to Secondhand Smoke Among Nonsmokers — United States, 1988–2014. MMWR Morb Mortal Wkly Rep [Internet]. 2018;67:1342–6. Available from: http://www.cdc.gov/mmwr/volumes/67/wr/mm6748a3.htm?s_cid=mm6748a3_w
59. Jeon J, Holford TR, Levy DT, Feuer EJ, Cao P, Tam J, et al. Smoking and Lung Cancer Mortality in the United States From 2015 to 2065. Ann Intern Med [Internet]. American College of Physicians; 2018 [cited 2019 Apr 16];169:684. Available from: http://annals.org/article.aspx?doi=10.7326/M18-1250
60. Bonnie RJ, Stratton K, Kwan LY, editors. Public Health Implications of Raising the Minimum Age of Legal Access to Tobacco Products [Internet]. Washington, D.C.: National Academies Press; 2015 [cited 2019 May 21]. Available from: http://www.nap.edu/catalog/18997
61. Xu X, Bishop EE, Kennedy SM, Simpson SA, Pechacek TF. Annual Healthcare Spending Attributable to Cigarette Smoking. Am J Prev Med [Internet]. 2015 [cited 2019 Jun 19];48:326–33. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25498551
62. Warren GW, Cartmell KB, Garrett-Mayer E, Salloum RG, Cummings KM. Attributable Failure of First-line Cancer Treatment and Incremental Costs Associated With Smoking by Patients With Cancer. JAMA Netw Open [Internet]. American Medical Association; 2019 [cited 2019 Jun 19];2:e191703. Available from: http://jamanetworkopen.jamanetwork.com/article.aspx?doi=10.1001/jamanetworkopen.2019.1703
63. MacMonegle AJ, Nonnemaker J, Duke JC, Farrelly MC, Zhao X, Delahanty JC, et al. Cost-Effectiveness Analysis of The Real Cost Campaign’s Effect on Smoking Prevention. Am J Prev Med [Internet]. Elsevier Inc.; 2018;55:319–25. Available from: https://doi.org/10.1016/j.amepre.2018.05.006
64. Christensen CH, Rostron B, Cosgrove C, Altekruse SF, Hartman AM, Gibson JT, et al. Association of Cigarette, Cigar, and Pipe Use With Mortality Risk in the US Population. JAMA Intern Med [Internet]. American Medical Association; 2018 [cited 2018 May 4];178:469. Available from: http://archinte.jamanetwork.com/article.aspx?doi=10.1001/jamainternmed.2017.8625
65. Epidemic TE, Youth A. Surgeon General ’ s Advisory on E-cigarette Use Among Youth The E-cigarette Epidemic Among Youth E-cigarettes Come in Many Shapes and Sizes You Can Take Action. 2018;2–5.
66. Stratton K, Kwan LY, Eaton DL, Effects H, Delivery N, Health P, et al. Public Health Consequences of E-Cigarettes [Internet]. National Academies Press; 2018. Available from: https://www.nap.edu/catalog/24952
67. King BA, Gammon DG, Marynak KL, Rogers T. Electronic Cigarette Sales in the United States, 2013-2017. JAMA [Internet]. 2018 [cited 2019 Jun 19];320:1379–80. Available from: http://jama.jamanetwork.com/article.aspx?doi=10.1001/jama.2018.10488
68. Gentzke AS, Creamer M, Cullen KA, Ambrose BK, Willis G. Vital Signs : Tobacco Product Use Among Middle and High School Students — United States , 2011 – 2018. 2019;68:2011–8.
69. Bhatta DN, Glantz SA. Electronic Cigarette Use and Myocardial Infarction Among Adults in the US Population Assessment of Tobacco and Health. J Am Heart Assoc [Internet]. 2019 [cited 2019 Jul 16];8. Available from: https://www.ahajournals.org/doi/10.1161/JAHA.119.012317
70. https://www.fda.gov/tobacco-products/ctp-newsroom/some-e-cigarette-users-are-having-seizures-most-reports-involving-youth-and-young-adults. Some E-cigarette Users Are Having Seizures, Most Reports Involving Youth and Young Adults | FDA [Internet]. [cited 2019 May 9]. Available from: https://www.fda.gov/tobacco-products/ctp-newsroom/some-e-cigarette-users-are-having-seizures-most-reports-involving-youth-and-young-adults
71. U.S. Department of Health and Human Services. E-Cigarette Use Among Youth and Young Adults. A Report of the Surgeon General. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion.
72. Boykan R, Messina CR, Chateau G, Eliscu A, Tolentino J, Goniewicz ML. Self-Reported Use of Tobacco, E-cigarettes, and Marijuana Versus Urinary Biomarkers. Pediatrics [Internet]. 2019 [cited 2019 Jun 19];143:e20183531. Available from: http://www.ncbi.nlm.nih.gov/pubmed/31010908
73. Goniewicz ML, Boykan R, Messina CR, Eliscu A, Tolentino J. High exposure to nicotine among adolescents who use Juul and other vape pod systems (‘pods’). Tob Control [Internet]. 2018 [cited 2019 May 22];tobaccocontrol-2018-054565. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30194085
74. Loukas A, Marti CN, Cooper M, Pasch KE, Perry CL. Exclusive e-cigarette use predicts cigarette initiation among college students. Addict Behav [Internet]. Elsevier; 2018;76:343–7. Available from: http://dx.doi.org/10.1016/j.addbeh.2017.08.023
75. Sung H, Siegel RL, Torre LA, Pearson‐Stuttard J, Islami F, Fedewa SA, et al. Global patterns in excess body weight and the associated cancer burden. CA Cancer J Clin [Internet]. 2018 [cited 2019 Jun 19];69:caac.21499. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30548482
76. Christopher G, Fleming D, Spencer T, Beck S. The State Obesity, 2018. 2018; Available from: www.tfah.org.
77. Lauby‑secretan B, Scoccianti C, Loomis D, Grosse Y, Bianchini F, Straif K. Body Fatness and Cancer — Viewpoint of the IARC Working Group. 2016;8.
78. Body fatness and weight gain and the risk of cancer. World Cancer Res Fund/American Inst Cancer Res Contin Updat Proj Expert Rep 2018 Body fatness Weight gain risk cancer Available dietandcancerreport.org. 2018;
79. World Cancer Research Fund/American Institute for Cancer Research. Continuous Update Project Expert Report 2018. Physical activity and the risk of cancer. Available at dietandcancerreport.org The.
80. Zhang FF, Cudhea F, Shan Z, Michaud DS, Imamura F, Eom H, et al. Preventable Cancer Burden Associated with Poor Diet in the United States. JNCI Cancer Spectr [Internet]. 2019 [cited 2019 Jun 19]; Available from: https://academic.oup.com/jncics/advance-article/doi/10.1093/jncics/pkz034/5492023
81. Afshin A, Sur PJ, Fay KA, Cornaby L, Ferrara G, Salama JS, et al. Health effects of dietary risks in 195 countries, 1990–2017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet [Internet]. 2019;6736. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0140673619300418
82. Agriculture USD of H and HS and USD of. 2015 – 2020 Dietary Guidelines for Americans. 2015 – 2020 Diet Guidel Am (8th Ed. 2015;18.
83. Daepp MIG, Gortmaker SL, Wang YC, Long MW, Kenney EL. WIC Food Package Changes: Trends in Childhood Obesity Prevalence. Pediatrics [Internet]. 2019 [cited 2019 Jun 19];143:e20182841. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30936251
84. Geserick M, Vogel M, Gausche R, Lipek T, Spielau U, Keller E, et al. Acceleration of BMI in Early Childhood and Risk of Sustained Obesity. N Engl J Med [Internet]. Massachusetts Medical Society; 2018 [cited 2019 May 28];379:1303–12. Available from: http://www.nejm.org/doi/10.1056/NEJMoa1803527
85. Levi Z, Rottenberg Y, Twig G, Katz L, Leiba A, Derazne E, et al. Adolescent overweight and obesity and the risk for pancreatic cancer among men and women: A nationwide study of 1.79 million Israeli adolescents. Cancer [Internet]. John Wiley & Sons, Ltd; 2019 [cited 2019 May 28];125:118–26. Available from: http://doi.wiley.com/10.1002/cncr.31764
86. Ward ZJ, Long MW, Resch SC, Giles CM, Cradock AL, Gortmaker SL, et al. Simulation of Growth Trajectories of Childhood Obesity into Adulthood. N Engl J Med [Internet]. 2017;377:2145–53. Available from: http://www.nejm.org/doi/10.1056/NEJMoa1703860
87. American Cancer Society. Cancer Prevention & Early Detection Facts & Figures 2017-2018.
88. Rosiner A, Herrick K, Gahche JJ, Park S. Sugar-sweetened Beverage Consumption Among U.S. Youth, 2011–2014. NCHS Data Brief [Internet]. 2017;1–7. Available from: http://origin.glb.cdc.gov/mmwr/preview/mmwrhtml/mm6332a2.htm?s_cid=mm6332a2_w
89. Rosiner A, Herrick K, Gahche JJ, Park S, Kumar G, Pan L, et al. Sugar-sweetened beverage consumption among adults-18 States, 2012. Morb Mortal Wkly Rep [Internet]. 2014;63:686–90. Available from: http://origin.glb.cdc.gov/mmwr/preview/mmwrhtml/mm6332a2.htm?s_cid=mm6332a2_w
90. Lee MM, Falbe J, Schillinger D, Basu S, McCulloch CE, Madsen KA. Sugar-Sweetened Beverage Consumption 3 Years After the Berkeley, California, Sugar-Sweetened Beverage Tax. Am J Public Health. 2019;109:637–9.
91. Roberto CA, Lawman HG, Levasseur MT, Mitra N, Peterhans A, Herring B, et al. Association of a Beverage Tax on Sugar-Sweetened and Artificially Sweetened Beverages with Changes in Beverage Prices and Sales at Chain Retailers in a Large Urban Setting. JAMA – J Am Med Assoc. 2019;321:1799–810.
92. Marshall CH, Al‐Mallah MH, Dardari Z, Brawner CA, Lamerato LE, Keteyian SJ, et al. Cardiorespiratory fitness and incident lung and colorectal cancer in men and women: Results from the Henry Ford Exercise Testing (FIT) cohort. Cancer [Internet]. 2019 [cited 2019 Jun 19];cncr.32085. Available from: http://www.ncbi.nlm.nih.gov/pubmed/31056756
93. Ussery EN, Fulton JE, Galuska DA, Katzmarzyk PT, Carlson SA. Joint Prevalence of Sitting Time and Leisure-Time Physical Activity Among US Adults, 2015-2016. JAMA [Internet]. American Medical Association; 2018 [cited 2019 Jun 19];320:2036. Available from: http://jama.jamanetwork.com/article.aspx?doi=10.1001/jama.2018.17797
94. National Physical Activity Plan Alliance. The 2018 United States Report Card on Physical Activity for Children and Youth. Washington, DC: National Physical Activity Plan Alliance, 2018. 2001;8:33–42.
95. Du Y, Liu B, Sun Y, Snetselaar LG, Wallace RB, Bao W. Trends in Adherence to the Physical Activity Guidelines for Americans for Aerobic Activity and Time Spent on Sedentary Behavior Among US Adults, 2007 to 2016. JAMA Netw Open [Internet]. 2019;2:e197597. Available from: https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2739044
96. Piercy KL, Troiano RP, Ballard RM, Carlson SA, Fulton JE, Galuska DA, et al. The Physical Activity Guidelines for Americans. JAMA [Internet]. American Medical Association; 2018 [cited 2019 Jun 19];320:2020. Available from: http://jama.jamanetwork.com/article.aspx?doi=10.1001/jama.2018.14854
97. Alcoholic drinks and the risk of cancer. This part World Cancer Res Fund/American Inst Cancer Res Contin Updat Proj Expert Rep 2018 Alcohol Drink risk cancer Available dietandcancerreport.org. 2018;
98. Xi B, Veeranki SP, Zhao M, Ma C, Yan Y, Mi J. Relationship of Alcohol Consumption to All-Cause, Cardiovascular, and Cancer-Related Mortality in U.S. Adults. J Am Coll Cardiol [Internet]. Elsevier; 2017 [cited 2018 Apr 3];70:913–22. Available from: https://www.sciencedirect.com/science/article/pii/S0735109717379986?_rdoc=1&_fmt=high&_origin=gateway&_docanchor=&md5=b8429449ccfc9c30159a5f9aeaa92ffb&dgcid=raven_sd_recommender_email
99. White AJ, DeRoo LA, Weinberg CR, Sandler DP. Lifetime alcohol intake, binge drinking behaviors, and breast cancer risk. Am J Epidemiol. 2017;186:541–9.
100. LoConte NK, Brewster AM, Kaur JS, Merrill JK, Alberg AJ. Alcohol and Cancer: A Statement of the American Society of Clinical Oncology. J Clin Oncol [Internet]. 2017;JCO.2017.76.115. Available from: http://ascopubs.org/doi/10.1200/JCO.2017.76.1155

References 101-150

101. Hydes TJ, Burton R, Inskip H, Bellis MA, Sheron N. A comparison of gender-linked population cancer risks between alcohol and tobacco: how many cigarettes are there in a bottle of wine? BMC Public Health [Internet]. BioMed Central; 2019 [cited 2019 May 10];19:316. Available from: https://bmcpublichealth.biomedcentral.com/articles/10.1186/s12889-019-6576-9
102. Kranzler HR, Soyka M. Diagnosis and pharmacotherapy of alcohol use disorder a review. JAMA – J Am Med Assoc. 2018;320:815–24.
103. WHO. Global status report on alcohol and health. World Heal Organ [Internet]. 2014;1–100. Available from: http://www.who.int/substance_abuse/publications/global_alcohol_report/msbgsruprofiles.pdf
104. GBD 2016 Alcohol and Drug Use Collaborators L, Charlson F, Ferrari A, Santomauro D, Erskine H, Mantilla-Herrara A, et al. The global burden of disease attributable to alcohol and drug use in 195 countries and territories, 1990-2016: A systematic analysis for the Global Burden of Disease Study 2016. The lancet Psychiatry [Internet]. Elsevier; 2018 [cited 2019 May 10];5:987–1012. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30392731
105. World Health Organization., World Health Organization, World Health Organization. Management of Substance Abuse Team. Global status report on alcohol and health 2018.
106. Akinyemiju T, Abera S, Ahmed M, Alam N, Alemayohu MA, Allen C, et al. The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level. JAMA Oncol [Internet]. 2017;98121. Available from: http://oncology.jamanetwork.com/article.aspx?doi=10.1001/jamaoncol.2017.3055
107. Dennis LK, Vanbeek MJ, Beane Freeman LE, Smith BJ, Dawson D V, Coughlin JA. Sunburns and risk of cutaneous melanoma: does age matter? A comprehensive meta-analysis. Ann Epidemiol [Internet]. NIH Public Access; 2008 [cited 2019 Jul 10];18:614–27. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18652979
108. Grossman DC, Curry SJ, Owens DK, Barry MJ, Caughey AB, Davidson KW, et al. Behavioral Counseling to Prevent Skin Cancer. Jama [Internet]. 2018;319:1134. Available from: http://jama.jamanetwork.com/article.aspx?doi=10.1001/jama.2018.1623
109. Davidson NE, Armstrong SA, Coussens LM, Cruz-Correa MR, DeBerardinis RJ, Doroshow JH, et al. AACR Cancer Progress Report 2016. Clin Cancer Res. United States; 2016;22:S1–137.
110. Holman DM, Freeman MB, Shoemaker ML. Trends in Melanoma Incidence Among Non-Hispanic Whites in the United States, 2005 to 2014. JAMA Dermatology [Internet]. American Medical Association; 2018 [cited 2018 Jun 4];154:361. Available from: http://archderm.jamanetwork.com/article.aspx?doi=10.1001/jamadermatol.2017.5541
111. Watson M, Garnett E, Guy GP, Holman DM. The surgeon general’s call to action to prevent skin cancer: facts for consumers. Int J Cancer Res Prev [Internet]. 2015;8:55–161. Available from: https://www.surgeongeneral.gov/library/calls/prevent-skin-cancer/call-to-action-prevent-skin-cancer.pdf
112. Guy GP, Watson M, Seidenberg AB, Hartman AM, Holman DM, Perna F. Trends in indoor tanning and its association with sunburn among US adults. J Am Acad Dermatol [Internet]. 2017 [cited 2018 Jun 18];76:1191–3. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0190962217300877
113. Guy GP, Berkowitz Z, Everett Jones S, Watson M, Richardson LC. Prevalence of Indoor Tanning and Association With Sunburn Among Youth in the United States. JAMA dermatology [Internet]. 2017 [cited 2018 Jun 18];153:387–90. Available from: http://archderm.jamanetwork.com/article.aspx?doi=10.1001/jamadermatol.2016.6273
114. IPSOS Public Affairs e-Nation survey conducted May 9, 2019 on behalf of The Blue Cross Blue Shield Association. 2017;32:81–4. Available from: https://bcbs.com/the-health-of-america
115. Bradford PT. Skin cancer in skin of color. Dermatology Nurs [Internet]. [cited 2019 Jun 19];21:170–7, 206; quiz 178. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19691228
116. Gloster HM, Neal K. Skin cancer in skin of color. J Am Acad Dermatol [Internet]. 2006 [cited 2019 Jun 19];55:741–60; quiz 761–4. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0190962205027301
117. Kasting ML, Giuliano AR, Reich RR, Roetzheim RG, Duong LM, Thomas E, et al. Hepatitis C virus screening trends: A 2016 update of the National Health Interview Survey. Cancer Epidemiol [Internet]. Elsevier; 2019 [cited 2019 May 14];60:112–20. Available from: https://www.sciencedirect.com/science/article/pii/S1877782118306805?via%3Dihub
118. Ryerson AB, Eheman CR, Altekruse SF, Ward JW, Jemal A, Sherman RL, et al. Annual Report to the Nation on the Status of Cancer, 1975-2012, featuring the increasing incidence of liver cancer. Cancer [Internet]. John Wiley & Sons, Ltd; 2016 [cited 2019 Jun 19];122:1312–37. Available from: http://doi.wiley.com/10.1002/cncr.29936
119. Geiger R, Steinert J, McElwee G, Carver J, Montanez R, Niewoehner J, et al. A Regional Analysis of Hepatitis C Virus Collaborative Care With Pharmacists in Indian Health Service Facilities. J Prim Care Community Health [Internet]. SAGE Publications; 2018 [cited 2019 Jul 18];9:2150132718807520. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30348039
120. HPV Vaccination for Cancer Prevention: Progress, Opportunities, and a Renewed Call to Action. A Report to the President of the United States from the Chair of the President’s Cancer Panel. Bethesda (MD): President’s Cancer Panel; 2018 Nov. 1971;281. Available from: https://prescancerpanel.cancer.gov
121. Van Dyne EA, Henley SJ, Saraiya M, Thomas CC, Markowitz LE, Benard VB. Trends in Human Papillomavirus–Associated Cancers — United States, 1999–2015. MMWR Morb Mortal Wkly Rep [Internet]. 2018;67:918–24. Available from: http://www.cdc.gov/mmwr/volumes/67/wr/mm6733a2.htm?s_cid=mm6733a2_w
122. McClung NM, Gargano JW, Park IU, Whitney E, Abdullah N, Ehlers S, et al. Estimated Number of Cases of High-Grade Cervical Lesions Diagnosed Among Women — United States, 2008 and 2016. MMWR Morb Mortal Wkly Rep [Internet]. 2019 [cited 2019 May 15];68:337–43. Available from: http://www.cdc.gov/mmwr/volumes/68/wr/mm6815a1.htm?s_cid=mm6815a1_w
123. McClung NM, Gargano JW, Bennett NM, Niccolai LM, Abdullah N, Griffin MR, et al. Trends in Human Papillomavirus Vaccine Types 16 and 18 in Cervical Precancers, 2008–2014. Cancer Epidemiol Biomarkers Prev [Internet]. 2019;28:2008–14. Available from: http://cebp.aacrjournals.org/lookup/doi/10.1158/1055-9965.EPI-18-0885
124. Guo F, Cofie LE, Berenson AB. Cervical Cancer Incidence in Young U.S. Females After Human Papillomavirus Vaccine Introduction. Am J Prev Med [Internet]. 2018 [cited 2019 Jul 14];55:197–204. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29859731
125. Drolet M, Bénard É, Pérez N, Brisson M, Ali H, Boily M-C, et al. Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: Updated systematic review and meta-analysis. Lancet [Internet]. 2019 [cited 2019 Jul 15]; Available from: https://linkinghub.elsevier.com/retrieve/pii/S0140673619302983
126. Hall MT, Simms KT, Lew J-B, Smith MA, Brotherton JM, Saville M, et al. The projected timeframe until cervical cancer elimination in Australia: A modelling study. Lancet Public Heal [Internet]. The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC-BY-NC-ND 4.0 license; 2018;2667:1–9. Available from: https://linkinghub.elsevier.com/retrieve/pii/S246826671830183X
127. Simms KT, Steinberg J, Caruana M, Smith MA, Lew J-B, Soerjomataram I, et al. Impact of scaled up human papillomavirus vaccination and cervical screening and the potential for global elimination of cervical cancer in 181 countries, 2020-99: A modelling study. Lancet Oncol [Internet]. Elsevier; 2019 [cited 2019 May 15];20:394–407. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30795950
128. AICR, WCRF. Lactation and the risk of cancer. 2018; Available from: https://www.wcrf.org/sites/default/files/Lactation.pdf
129. Palmer JR, Viscidi E, Troester MA, Hong C-C, Schedin P, Bethea TN, et al. Parity, lactation, and breast cancer subtypes in African American women: Results from the AMBER Consortium. J Natl Cancer Inst [Internet]. 2014 [cited 2019 Jun 19];106. Available from: https://academic.oup.com/jnci/article-lookup/doi/10.1093/jnci/dju237
130. Islami F, Liu Y, Jemal A, Zhou J, Weiderpass E, Colditz G, et al. Breastfeeding and breast cancer risk by receptor status–a systematic review and meta-analysis. Ann Oncol  Off J Eur Soc Med Oncol [Internet]. 2015 [cited 2019 Jun 19];26:2398–407. Available from: https://academic.oup.com/annonc/article-lookup/doi/10.1093/annonc/mdv379
131. Anstey EH, Chen J, Elam-Evans LD, Perrine CG. Racial and Geographic Differences in Breastfeeding — United States, 2011–2015. MMWR Morb Mortal Wkly Rep [Internet]. 2017 [cited 2019 Jun 21];66:723–7. Available from: http://www.cdc.gov/mmwr/volumes/66/wr/mm6627a3.htm
132. Chlebowski RT, Anderson G, Pettinger M, Lane D, Langer RD, Gilligan MA, et al. Estrogen Plus Progestin and Breast Cancer Detection by Means of Mammography and Breast Biopsy. Arch Intern Med [Internet]. 2008 [cited 2019 Jun 19];168:370. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18299491
133. Chlebowski RT, Kuller LH, Prentice RL, Stefanick ML, Manson JE, Gass M, et al. Breast Cancer after Use of Estrogen plus Progestin in Postmenopausal Women. N Engl J Med [Internet]. 2009 [cited 2019 Jun 19];360:573–87. Available from: http://www.nejm.org/doi/abs/10.1056/NEJMoa0807684
134. Ellingjord-Dale M, Vos L, Tretli S, Hofvind S, Dos-Santos-Silva I, Ursin G. Parity, hormones and breast cancer subtypes – results from a large nested case-control study in a national screening program. Breast Cancer Res [Internet]. 2017 [cited 2019 Jun 19];19:10. Available from: http://breast-cancer-research.biomedcentral.com/articles/10.1186/s13058-016-0798-x
135. Rosenberg L, Bethea TN, Viscidi E, Hong C-C, Troester MA, Bandera E V, et al. Postmenopausal Female Hormone Use and Estrogen Receptor-Positive and -Negative Breast Cancer in African American Women. J Natl Cancer Inst [Internet]. 2016 [cited 2019 Jun 19];108:djv361. Available from: https://academic.oup.com/jnci/article-lookup/doi/10.1093/jnci/djv361
136. National Cancer Institute. Cancer Trends Progress Report. 2013; Available from: http://progressreport.cancer.gov/
137. Loomis D, Grosse Y, Lauby-Secretan B, El Ghissassi F, Bouvard V, Benbrahim-Tallaa L, et al. The carcinogenicity of outdoor air pollution. Lancet Oncol [Internet]. 2013 [cited 2019 Jun 19];14:1262–3. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25035875
138. WHO. Air Pollution and Cancer – IARC Scientific Publication No. 161. Int. Agency Res. Cancer. 2013.
139. Curry SJ, Krist AH, Owens DK, Barry MJ, Caughey AB, Davidson KW, et al. Screening for Cervical Cancer. JAMA [Internet]. American Medical Association; 2018 [cited 2019 Jun 20];320:674. Available from: http://jama.jamanetwork.com/article.aspx?doi=10.1001/jama.2018.10897
140. What Are the Risk Factors for Lung Cancer? | CDC [Internet]. [cited 2019 Jun 20]. Available from: https://www.cdc.gov/cancer/lung/basic_info/risk_factors.htm
141. Kampman E. A First-Degree Relative with Colorectal Cancer: What Are We Missing? Cancer Epidemiol Biomarkers Prev [Internet]. American Association for Cancer Research; 2007 [cited 2019 Jun 20];16:1–3. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17220324
142. Wu L, Shi W, Long J, Guo X, Michailidou K, Beesley J, et al. A transcriptome-wide association study of 229,000 women identifies new candidate susceptibility genes for breast cancer. Nat Genet [Internet]. NIH Public Access; 2018 [cited 2019 Jun 20];50:968–78. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29915430
143. Manickam K, Buchanan AH, Schwartz MLB, Hallquist MLG, Williams JL, Rahm AK, et al. Exome Sequencing–Based Screening for BRCA1/2 Expected Pathogenic Variants Among Adult Biobank Participants. JAMA Netw Open [Internet]. American Medical Association; 2018 [cited 2019 Jun 20];1:e182140. Available from: http://jamanetworkopen.jamanetwork.com/article.aspxdoi=10.1001/jamanetworkopen.2018.2140
144. Beitsch PD, Whitworth PW, Hughes K, Patel R, Rosen B, Compagnoni G, et al. Underdiagnosis of Hereditary Breast Cancer: Are Genetic Testing Guidelines a Tool or an Obstacle? J Clin Oncol [Internet]. American Society of Clinical Oncology; 2019 [cited 2019 Jun 20];37:453–60. Available from: http://ascopubs.org/doi/10.1200/JCO.18.01631
145. Genetic Testing Fact Sheet – National Cancer Institute [Internet]. [cited 2019 Jun 20]. Available from: https://www.cancer.gov/about-cancer/causes-prevention/genetics/genetic-testing-fact-sheet#q4
146. Campbell JD, Mazzilli SA, Reid ME, Dhillon SS, Platero S, Beane J, et al. The Case for a Pre-Cancer Genome Atlas (PCGA). Cancer Prev Res [Internet]. 2016;9:119 LP – 124. Available from: http://cancerpreventionresearch.aacrjournals.org/content/9/2/119.abstract
147. Shewell LK, Wang JJ, Paton JC, Paton AW, Day CJ, Jennings MP. Detection of N-glycolylneuraminic acid biomarkers in sera from patients with ovarian cancer using an engineered N-glycolylneuraminic acid-specific lectin SubB2M. Biochem Biophys Res Commun [Internet]. Academic Press; 2018 [cited 2019 Jun 20];507:173–7. Available from: https://www.sciencedirect.com/science/article/pii/S0006291X18323957?via%3Dihub
148. Spira A, Yurgelun MB, Alexandrov L, Rao A, Bejar R, Polyak K, et al. Precancer Atlas to Drive Precision Prevention Trials. Cancer Res. United States; 2017;77:1510–41.
149. Rebbeck TR, Burns-White K, Chan AT, Emmons K, Freedman M, Hunter DJ, et al. Precision Prevention and Early Detection of Cancer: Fundamental Principles. Cancer Discov. United States; 2018;8:803–11.
150. White A, Thompson TD, White MC, Sabatino SA, Moor J de, Doria-Rose P V., et al. Cancer screening test use — United States, 2015. Morb Mortal Wkly Rep [Internet]. 2017;66:201–6. Available from: https://www.cdc.gov/mmwr/volumes/66/wr/mm6608a1.htm#suggestedcitation

References 151-200

151. Jemal A, Fedewa SA. Lung Cancer Screening With Low-Dose Computed Tomography in the United States—2010 to 2015. JAMA Oncol [Internet]. American Medical Association; 2017 [cited 2019 Jun 20];3:1278. Available from: http://oncology.jamanetwork.com/article.aspx?doi=10.1001/jamaoncol.2016.6416
152. Charkhchi P, Schabath MB. Modifiers of Cancer Screening Prevention Among Sexual and Gender Minorities in the Behavioral Risk Factor Surveillance System. J Am Coll Radiol [Internet]. Elsevier; 2019 [cited 2019 Jun 20];16:607–20. Available from: https://www.sciencedirect.com/science/article/pii/S1546144019302625
153. American Cancer Society. Colorectal Cancer Facts & Figures 2017-2019.
154. Freedman RA, Keating NL, Pace LE, Lii J, McCarthy EP, Schonberg MA. Use of Surveillance Mammography Among Older Breast Cancer Survivors by Life Expectancy. J Clin Oncol [Internet]. American Society of Clinical Oncology; 2017;35:3123–30. Available from: https://doi.org/10.1200/JCO.2016.72.1209
155. Calderwood AH, Anderson JC, Robinson CM, Butterly LF. Endoscopist Specialty Predicts the Likelihood of Recommending Cessation of Colorectal Cancer Screening in Older Adults. Am J Gastroenterol [Internet]. 2018 [cited 2019 Jun 20];113:1862–71. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30390031
156. Schoenborn NL, Huang J, Sheehan OC, Wolff JL, Roth DL, Boyd CM. Influence of Age, Health, and Function on Cancer Screening in Older Adults with Limited Life Expectancy. J Gen Intern Med [Internet]. 2019 [cited 2019 Jun 20];34:110–7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30402822
157. Rice K, Gressard L, DeGroff A, Gersten J, Robie J, Leadbetter S, et al. Increasing colonoscopy screening in disparate populations: Results from an evaluation of patient navigation in the New Hampshire Colorectal Cancer Screening Program. Cancer [Internet]. 2017 [cited 2019 Jun 20];123:3356–66. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28464213
158. Dougherty MK, Brenner AT, Crockett SD, Gupta S, Wheeler SB, Coker-Schwimmer M, et al. Evaluation of Interventions Intended to Increase Colorectal Cancer Screening Rates in the United States. JAMA Intern Med [Internet]. American Medical Association; 2018 [cited 2019 Jun 20];178:1645. Available from: http://archinte.jamanetwork.com/article.aspx?doi=10.1001/jamainternmed.2018.4637
159. Huo J, Hong Y-R, Bian J, Guo Y, Wilkie DJ, Mainous AG. Low Rates of Patient-Reported Physician–Patient Discussion about Lung Cancer Screening among Current Smokers: Data from Health Information National Trends Survey. Cancer Epidemiol Biomarkers Prev [Internet]. American Association for Cancer Research; 2019 [cited 2019 Jun 20];28:963–73. Available from: http://www.ncbi.nlm.nih.gov/pubmed/31023697
160. Brenner AT, Malo TL, Margolis M, Elston Lafata J, James S, Vu MB, et al. Evaluating Shared Decision Making for Lung Cancer Screening. JAMA Intern Med [Internet]. American Medical Association; 2018 [cited 2019 Jun 20];178:1311. Available from: http://archinte.jamanetwork.com/article.aspx?doi=10.1001/jamainternmed.2018.3054
161. IQVIA Institute for Human Data Science. Global Oncology Trends 2019. Glob Oncol Trends [Internet]. 2019;2. Available from: https://morningconsult.com/wp-content/uploads/2017/06/QuintilesIMS-Institute-Oncology-Report.pdf
162. Wong CH, Siah KW, Lo AW. Estimation of clinical trial success rates and related parameters. Biostatistics [Internet]. Narnia; 2019 [cited 2019 Jun 20];20:273–86. Available from: https://academic.oup.com/biostatistics/article/20/2/273/4817524
163. Bhatt DL, Mehta C. Adaptive Designs for Clinical Trials. N Engl J Med [Internet]. Massachusetts Medical Society; 2016;375:65–74. Available from: http://dx.doi.org/10.1056/NEJMra1510061
164. Prowell TM, Theoret MR, Pazdur R. Seamless Oncology-Drug Development. N Engl J Med [Internet]. Massachusetts Medical Society; 2016;374:2001–3. Available from: http://dx.doi.org/10.1056/NEJMp1603747
165. Woodcock J, LaVange LM. Master Protocols to Study Multiple Therapies, Multiple Diseases, or Both. N Engl J Med [Internet]. 2017;377:62–70. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28679092
166. Drilon A, Laetsch TW, Kummar S, DuBois SG, Lassen UN, Demetri GD, et al. Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children. N Engl J Med [Internet]. Massachusetts Medical Society; 2018 [cited 2019 Jun 20];378:731–9. Available from: http://www.nejm.org/doi/10.1056/NEJMoa1714448
167. Clinical Development Success Rates. 2016;
168. Unger JM, Cook E, Tai E, Bleyer A. The Role of Clinical Trial Participation in Cancer Research: Barriers, Evidence, and Strategies. Am Soc Clin Oncol Educ B [Internet]. 2016;36:185–98. Available from: http://meetinglibrary.asco.org/content/156686-176
169. VH M, HM K, CP G. Participation in cancer clinical trials: Race-, sex-, and age-based disparities. JAMA [Internet]. 2004;291:2720–6. Available from: http://dx.doi.org/10.1001/jama.291.22.2720
170. Aristizabal P, Singer J, Cooper R, Wells KJ, Nodora J, Milburn M, et al. Participation in Pediatric Oncology Research Protocols: Racial/ethnic, Language and Age-based Disparities. Pediatr Blood Cancer [Internet]. NIH Public Access; 2015 [cited 2019 Jun 20];62:1337. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4482802/
171. Bleyer A, Budd T, Montello M. Adolescents and young adults with cancer. Cancer [Internet]. John Wiley & Sons, Ltd; 2006 [cited 2019 Jul 10];107:1645–55. Available from: http://doi.wiley.com/10.1002/cncr.22102
172. Stensland KD, McBride RB, Latif A, Wisnivesky J, Hendricks R, Roper N, et al. Adult cancer clinical trials that fail to complete: an epidemic? J Natl Cancer Inst [Internet]. 2014 [cited 2019 Jul 18];106. Available from: https://academic.oup.com/jnci/article-lookup/doi/10.1093/jnci/dju229
173. Bennette CS, Ramsey SD, McDermott CL, Carlson JJ, Basu A, Veenstra DL. Predicting Low Accrual in the National Cancer Institute’s Cooperative Group Clinical Trials. J Natl Cancer Inst [Internet]. Oxford University Press; 2016 [cited 2019 Jul 18];108. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26714555
174. American Cancer Society. Cancer Facts & Figures for African Americans 2019-2021. Atlanta: American Cancer Society, 2019. 2019;
175. Cder FDA. DRUG TRIALS SNAPSHOTS. 2018;
176. von Minckwitz G, Huang C-S, Mano MS, Loibl S, Mamounas EP, Untch M, et al. Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. N Engl J Med [Internet]. Massachusetts Medical Society; 2019 [cited 2019 Jun 20];380:617–28. Available from: http://www.nejm.org/doi/10.1056/NEJMoa1814017
177. Neuner JM, Kong A, Blaes A, Riley D, Chrischilles E, Smallwood A, et al. The association of socioeconomic status with receipt of neoadjuvant chemotherapy. Breast Cancer Res Treat [Internet]. 2019 [cited 2019 Jun 20];173:179–88. Available from: http://link.springer.com/10.1007/s10549-018-4954-0
178. Fiala MA, Wildes TM. Racial disparities in treatment use for multiple myeloma. Cancer. United States; 2017;123:1590–6.
179. Caram ME V., Ross R, Lin P, Mukherjee B. Factors Associated With Use of Sipuleucel-T to Treat Patients With Advanced Prostate Cancer. JAMA Netw Open [Internet]. American Medical Association; 2019 [cited 2019 Jun 20];2:e192589. Available from: http://jamanetworkopen.jamanetwork.com/article.aspx?doi=10.1001/jamanetworkopen.2019.2589
180. Dess RT, Hartman HE, Mahal BA, Soni PD, Jackson WC, Cooperberg MR, et al. Association of Black Race With Prostate Cancer–Specific and Other-Cause Mortality. JAMA Oncol [Internet]. 2019 [cited 2019 Jun 20]; Available from: http://www.ncbi.nlm.nih.gov/pubmed/31120534
181. Fillmore NR, Yellapragada S V, Ifeorah C, Mehta A, Cirstea D, White PS, et al. With equal access, African American patients have superior survival compared to white patients with multiple myeloma: A VA study. Blood [Internet]. 2019 [cited 2019 Jun 20];133:2615–8. Available from: http://www.bloodjournal.org/lookup/doi/10.1182/blood.2019000406
182. Ransome E, Tong L, Espinosa J, Chou J, Somnay V, Munene G. Trends in surgery and disparities in receipt of surgery for intrahepatic cholangiocarcinoma in the US: 2005-2014. J Gastrointest Oncol [Internet]. AME Publications; 2019 [cited 2019 Jun 20];10:339–47. Available from: http://www.ncbi.nlm.nih.gov/pubmed/31032103
183. Zhang S, Liu Y, Yun S, Lian M, Komaie G, Colditz GA. Impacts of Neighborhood Characteristics on Treatment and Outcomes in Women with Ductal Carcinoma In Situ of the Breast. Cancer Epidemiol Biomarkers Prev [Internet]. American Association for Cancer Research; 2018 [cited 2019 Jun 20];27:1298–306. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30108100
184. National Academies of Science, Engineering  and M. Appropriate use of advanced technologies for radiation therapy and surgery in oncology: Workshop summary.
185. Main cancer treatments. [cited 2019 Jul 17]; Available from: http://www.ncin.org.uk/cancer_type_and_topic_specific_work/topic_specific_work/main_cancer_treatments
186. Liu VX, Rosas E, Hwang JC, Cain E, Foss-Durant A, Clopp M, et al. The Kaiser Permanente Northern California Enhanced Recovery After Surgery Program: Design, Development, and Implementation. Perm J [Internet]. Kaiser Permanente; 2017 [cited 2019 Jun 20];21:17–003. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28746028
187. Li S, Zhou K, Che G, Yang M, Su J, Shen C, et al. Enhanced recovery programs in lung cancer surgery: Systematic review and meta-analysis of randomized controlled trials. Cancer Manag Res [Internet]. 2017 [cited 2019 Jun 20];9:657–70. Available from: https://www.dovepress.com/enhanced-recovery-programs-in-lung-cancer-surgery-systematic-review-an-peer-reviewed-article-CMAR
188. Ngo-Huang A, Fontillas RC, Gupta E, Sahai SK, Popovich S, Andrabi T, et al. Implementing prehabilitation as part of enhanced recovery after surgery (ERAS) efforts at a comprehensive cancer center: A team-based approach. J Clin Oncol [Internet]. American Society of Clinical Oncology; 2018 [cited 2019 Jun 20];36:137–137. Available from: http://ascopubs.org/doi/10.1200/JCO.2018.36.30_suppl.137
189. Gustafsson UO, Scott MJ, Hubner M, Nygren J, Demartines N, Francis N, et al. Guidelines for Perioperative Care in Elective Colorectal Surgery: Enhanced Recovery After Surgery (ERAS®) Society Recommendations: 2018. World J Surg [Internet]. Springer International Publishing; 2019 [cited 2019 Jun 20];43:659–95. Available from: http://link.springer.com/10.1007/s00268-018-4844-y
190. Santa Mina D, Brahmbhatt P, Lopez C, Baima J, Gillis C, Trachtenberg L, et al. The Case for Prehabilitation Prior to Breast Cancer Treatment. PM&R [Internet]. 2017 [cited 2019 Jun 20];9:S305–16. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28942905
191. Gillis C, Li C, Lee L, Awasthi R, Augustin B, Gamsa A, et al. Prehabilitation versus Rehabilitation. Anesthesiology [Internet]. 2014 [cited 2019 Jun 20];121:937–47. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25076007
192. Mariette C, Markar SR, Dabakuyo-Yonli TS, Meunier B, Pezet D, Collet D, et al. Hybrid Minimally Invasive Esophagectomy for Esophageal Cancer. N Engl J Med [Internet]. Massachusetts Medical Society; 2019 [cited 2019 Jun 20];380:152–62. Available from: http://www.nejm.org/doi/10.1056/NEJMoa1805101
193. Ramirez PT, Frumovitz M, Pareja R, Lopez A, Vieira M, Ribeiro R, et al. Minimally Invasive versus Abdominal Radical Hysterectomy for Cervical Cancer. N Engl J Med [Internet]. Massachusetts Medical Society; 2018 [cited 2019 Jun 20];379:1895–904. Available from: http://www.nejm.org/doi/10.1056/NEJMoa1806395
194. Melamed A, Margul DJ, Chen L, Keating NL, del Carmen MG, Yang J, et al. Survival after Minimally Invasive Radical Hysterectomy for Early-Stage Cervical Cancer. N Engl J Med [Internet]. Massachusetts Medical Society; 2018 [cited 2019 Jun 20];379:1905–14. Available from: http://www.nejm.org/doi/10.1056/NEJMoa1804923
195. Galimberti V, Cole BF, Viale G, Veronesi P, Vicini E, Intra M, et al. Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial. Lancet Oncol [Internet]. Elsevier; 2018 [cited 2019 Jun 20];19:1385–93. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30196031
196. Harter P, Sehouli J, Lorusso D, Reuss A, Vergote I, Marth C, et al. A Randomized Trial of Lymphadenectomy in Patients with Advanced Ovarian Neoplasms. N Engl J Med [Internet]. Massachusetts Medical Society; 2019 [cited 2019 Jun 20];380:822–32. Available from: http://www.nejm.org/doi/10.1056/NEJMoa1808424
197. Brown PD, Ballman K V, Cerhan JH, Anderson SK, Carrero XW, Whitton AC, et al. Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC.3): A multicentre, randomised, controlled, phase 3 trial. Lancet Oncol. England; 2017;18:1049–60.
198. Haviland JS, Owen JR, Dewar JA, Agrawal RK, Barrett J, Barrett-Lee PJ, et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials. Lancet Oncol. England; 2013;14:1086–94.
199. Avkshtol V, Li T, Hallman MA, Greenberg R, Price RA, Uzzo RG, et al. 10-Year Update of a Randomized Prospective Trial of Conventional Versus Hypofractionated Radiation Therapy for Localized Prostate Cancer. Int J Radiat Oncol [Internet]. Elsevier; 2018 [cited 2019 Jun 20];102:S30–1. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0360301618310617
200. Parker CC, James ND, Brawley CD, Clarke NW, Hoyle AP, Ali A, et al. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet (London, England) [Internet]. Elsevier; 2018 [cited 2019 Jun 20];392:2353–66. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30355464

References 201-250

201. Boevé LMS, Hulshof MCCM, Vis AN, Zwinderman AH, Twisk JWR, Witjes WPJ, et al. Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomised Clinical Trial: Data from the HORRAD Trial. Eur Urol [Internet]. 2019 [cited 2019 Jun 20];75:410–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30266309
202. Lyengar P, Wardak Z, Gerber DE, Tumati V, Ahn C, Hughes RS, et al. Consolidative Radiotherapy for Limited Metastatic Non-Small-Cell Lung Cancer: A Phase 2 Randomized Clinical Trial. JAMA Oncol. United States; 2018;4:e173501.
203. Gomez DR, Tang C, Zhang J, Blumenschein GR, Hernandez M, Lee JJ, et al. Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non–Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study. J Clin Oncol [Internet]. 2019 [cited 2019 Jun 20];37:1558–65. Available from: http://www.ncbi.nlm.nih.gov/pubmed/31067138
204. Angiolillo AL, Schore RJ, Devidas M, Borowitz MJ, Carroll AJ, Gastier-Foster JM, et al. Pharmacokinetic and pharmacodynamic properties of calaspargase pegol Escherichia coli L-asparaginase in the treatment of patients with acute lymphoblastic leukemia: results from Children’s Oncology Group Study AALL07P4. J Clin Oncol [Internet]. American Society of Clinical Oncology; 2014 [cited 2019 Jun 20];32:3874–82. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25348002
205. Shitara K, Doi T, Dvorkin M, Mansoor W, Arkenau H-T, Prokharau A, et al. Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol [Internet]. 2018 [cited 2019 Jun 20];19:1437–48. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30355453
206. J Clin Oncol 37, 2019 (suppl; abstr 4006) [Internet]. [cited 2019 Jun 20]. Available from: https://abstracts.asco.org/239/AbstView_239_259067.html
207. Spring LM, Fell G, Arfe A, Trippa L, Greenup R, Reynolds K, Smith BL, Moy B, Isakoff SJ, Parmigiani G BA. Pathological complete response after neoadjuvant chemotherapy and impact on breast cancer recurrence and mortality, stratified by breast cancer subtypes and adjuvant chemotherapy usage: Individual patient-level meta-analyses of over 27,000 patients [Internet]. [cited 2019 Jun 20]. Available from: https://www.abstracts2view.com/sabcs18/view.php?nu=SABCS18L_1698&terms
208. Katzenstein HM, Langham MR, Malogolowkin MH, Krailo MD, Towbin AJ, McCarville MB, et al. Minimal adjuvant chemotherapy for children with hepatoblastoma resected at diagnosis (AHEP0731): A Children’s Oncology Group, multicentre, phase 3 trial. Lancet Oncol [Internet]. 2019 [cited 2019 Jun 20];20:719–27. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30975630
209. Brock PR, Maibach R, Childs M, Rajput K, Roebuck D, Sullivan MJ, et al. Sodium Thiosulfate for Protection from Cisplatin-Induced Hearing Loss. N Engl J Med [Internet]. Massachusetts Medical Society; 2018 [cited 2019 Jul 15];378:2376–85. Available from: http://www.nejm.org/doi/10.1056/NEJMoa1801109
210. American Cancer Society. Breast Cancer Facts & Figures 2017-2018. 2018;
211. André F, Ciruelos E, Rubovszky G, Campone M, Loibl S, Rugo HS, et al. Alpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer. N Engl J Med [Internet]. 2019 [cited 2019 Jun 21];380:1929–40. Available from: http://www.nejm.org/doi/10.1056/NEJMoa1813904
212. Litton JK, Rugo HS, Ettl J, Hurvitz SA, Gonçalves A, Lee K-H, et al. Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation. N Engl J Med [Internet]. Massachusetts Medical Society; 2018 [cited 2019 Jun 20];379:753–63. Available from: http://www.nejm.org/doi/10.1056/NEJMoa1802905
213. Kurian AW, Griffith KA, Hamilton AS, Ward KC, Morrow M, Katz SJ, et al. Genetic Testing and Counseling Among Patients With Newly Diagnosed Breast Cancer. JAMA [Internet]. American Medical Association; 2017 [cited 2017 Feb 27];317:531. Available from: http://jama.jamanetwork.com/article.aspx?doi=10.1001/jama.2016.16918
214. Helsten T, Elkin S, Arthur E, Tomson BN, Carter J, Kurzrock R. The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing. Clin Cancer Res [Internet]. 2016 [cited 2019 Jun 21];22:259–67. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26373574
215. Yanada M, Matsuo K, Suzuki T, Kiyoi H, Naoe T. Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations for acute myeloid leukemia: a meta-analysis. Leukemia [Internet]. 2005 [cited 2019 Jun 21];19:1345–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15959528
216. Perl AE, Martinelli G, Cortes JE, Neubauer A, Berman E, Paolini S, et al. Abstract CT184: Gilteritinib significantly prolongs overall survival in patients with FLT3 -mutated ( FLT3 mut+ ) relapsed/refractory (R/R) acute myeloid leukemia (AML): Results from the Phase III ADMIRAL trial. Clin Trials [Internet]. American Association for Cancer Research; 2019 [cited 2019 Jul 18]. page CT184–CT184. Available from: http://cancerres.aacrjournals.org/lookup/doi/10.1158/1538-7445.SABCS18-CT184
217. Cortes JE, Douglas Smith B, Wang ES, Merchant A, Oehler VG, Arellano M, et al. Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high-risk MDS: Phase 2 study results. Am J Hematol [Internet]. Wiley-Blackwell; 2018 [cited 2019 Jun 21];93:1301–10. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30074259
218. Cortes JE, Heidel FH, Hellmann A, Fiedler W, Smith BD, Robak T, et al. Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome. Leukemia [Internet]. Nature Publishing Group; 2019 [cited 2019 Jun 21];33:379–89. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30555165
219. DiNardo CD, Pratz K, Pullarkat V, Jonas BA, Arellano M, Becker PS, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood [Internet]. The American Society of Hematology; 2019 [cited 2019 Jun 21];133:7–17. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30361262
220. Flinn IW, Hillmen P, Montillo M, Nagy Z, Illés Á, Etienne G, et al. The phase 3 DUO trial: Duvelisib vs ofatumumab in relapsed and refractory CLL/SLL. Blood [Internet]. The American Society of Hematology; 2018 [cited 2019 Jun 21];132:2446–55. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30287523
221. Lopez-Rubio M, Garcia-Marco JA. Current and emerging treatment options for hairy cell leukemia. Onco Targets Ther [Internet]. Dove Press; 2015 [cited 2019 Jun 21];8:2147. Available from: http://www.dovepress.com/current-and-emerging-treatment-options-for-hairy-cell-leukemia-peer-reviewed-article-OTT
222. Kreitman RJ, Dearden C, Zinzani PL, Delgado J, Karlin L, Robak T, et al. Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia. Leukemia [Internet]. Nature Publishing Group; 2018 [cited 2019 Jun 21];32:1768–77. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30030507
223. Getta BM, Park JH, Tallman MS. Hairy cell leukemia: Past, present and future. Best Pract Res Clin Haematol [Internet]. NIH Public Access; 2015 [cited 2019 Jun 21];28:269–72. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26614906
224. Pemmaraju N, Lane AA, Sweet KL, Stein AS, Vasu S, Blum W, et al. Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm. N Engl J Med [Internet]. 2019 [cited 2019 Jun 21];380:1628–37. Available from: http://www.ncbi.nlm.nih.gov/pubmed/31018069
225. Fizazi K, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S, et al. Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer. N Engl J Med [Internet]. Massachusetts Medical Society; 2019 [cited 2019 Aug 2];380:1235–46. Available from: http://www.nejm.org/doi/10.1056/NEJMoa1815671
226. Saito S, Espinoza-Mercado F, Liu H, Sata N, Cui X, Soukiasian HJ. Current status of research and treatment for non-small cell lung cancer in never-smoking females. Cancer Biol Ther [Internet]. Taylor & Francis; 2017 [cited 2019 Jun 21];18:359–68. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28494184
227. Wu Y-L, Cheng Y, Zhou X, Lee KH, Nakagawa K, Niho S, et al. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. Lancet Oncol [Internet]. 2017 [cited 2019 Jun 21];18:1454–66. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28958502
228. Yoda S, Lin JJ, Lawrence MS, Burke BJ, Friboulet L, Langenbucher A, et al. Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer. Cancer Discov [Internet]. American Association for Cancer Research; 2018 [cited 2019 Jun 21];8:714–29. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29650534
229. Solomon BJ, Besse B, Bauer TM, Felip E, Soo RA, Camidge DR, et al. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study. Lancet Oncol [Internet]. 2018 [cited 2019 Jun 21];19:1654–67. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1470204518306491
230. Kudo M, Finn RS, Qin S, Han K-H, Ikeda K, Piscaglia F, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet [Internet]. 2018 [cited 2019 Jun 21];391:1163–73. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29433850
231. Abou-Alfa GK, Meyer T, Cheng A-L, El-Khoueiry AB, Rimassa L, Ryoo B-Y, et al. Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma. N Engl J Med [Internet]. 2018 [cited 2019 Jun 21];379:54–63. Available from: http://www.ncbi.nlm.nih.gov/pubmed/299727
232. Garon EB, Hellmann MD, Rizvi NA, Carcereny E, Leighl NB, Ahn M-J, et al. Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study. J Clin Oncol [Internet]. 2019 [cited 2019 Jul 15];JCO1900934. Available from: https://ascopubs.org/doi/10.1200/JCO.19.00934
233. Tang J, Shalabi A, Hubbard-Lucey VM. Comprehensive analysis of the clinical immuno-oncology landscape. Ann Oncol [Internet]. 2018 [cited 2018 Jun 8];29:84–91. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29228097
234. June CH, O’Connor RS, Kawalekar OU, Ghassemi S, Milone MC. CAR T cell immunotherapy for human cancer. Science (80- ) [Internet]. 2018;359:1361–5. Available from: http://www.sciencemag.org/lookup/doi/10.1126/science.aar6711
235. Adusumilli PS, Zauderer MG, Rusch VW, O’Cearbhaill RE, Zhu A, Ngai DA, et al. Abstract CT036: A phase I clinical trial of malignant pleural disease treated with regionally delivered autologous mesothelin-targeted CAR T cells: Safety and efficacy. Clin Trials [Internet]. American Association for Cancer Research; 2019 [cited 2019 Jul 18]. page CT036–CT036. Available from: http://cancerres.aacrjournals.org/lookup/doi/10.1158/1538-7445.SABCS18-CT03
236. Brunet JF, Denizot F, Luciani MF, Roux-Dosseto M, Suzan M, Mattei MG, et al. A new member of the immunoglobulin superfamily–CTLA-4. Nature. England; 1987;328:267–70.
237. Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A. United States; 2002;99:12293–7.
238. Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity. United States; 1995;3:541–7.
239. Waterhouse P, Penninger JM, Timms E, Wakeham A, Shahinian A, Lee KP, et al. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science. United States; 1995;270:985–8.
240. Nishimura H, Nose M, Hiai H, Minato N, Honjo T. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity. United States; 1999;11:141–51.
241. Linsley PS, Brady W, Urnes M, Grosmaire LS, Damle NK, Ledbetter JA. CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med. United States; 1991;174:561–9.
242. Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. United States; 2000;192:1027–34.
243. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science. United States; 1996;271:1734–6.
244. Sawyers CL, Abate-Shen C, Anderson KC, Barker A, Baselga J, Berger NA, et al. AACR Cancer Progress Report 2013. Clin Cancer Res. United States; 2013;19:S4-98.
245. Rogers HW, Weinstock MA, Feldman SR, Coldiron BM. Incidence Estimate of Nonmelanoma Skin Cancer (Keratinocyte Carcinomas) in the US Population, 2012. JAMA Dermatology [Internet]. American Medical Association; 2015 [cited 2019 Jun 21];151:1081. Available from: http://archderm.jamanetwork.com/article.aspx?doi=10.1001/jamadermatol.2015.1187
246. Migden MR, Rischin D, Schmults CD, Guminski A, Hauschild A, Lewis KD, et al. PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma. N Engl J Med [Internet]. Massachusetts Medical Society; 2018 [cited 2019 Jun 21];379:341–51. Available from: http://www.nejm.org/doi/10.1056/NEJMoa1805131
247. Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, et al. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. N Engl J Med [Internet]. Massachusetts Medical Society; 2018 [cited 2019 Jul 15];379:2108–21. Available from: http://www.nejm.org/doi/10.1056/NEJMoa1809615
248. Horn L, Mansfield AS, Szczęsna A, Havel L, Krzakowski M, Hochmair MJ, et al. First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. N Engl J Med [Internet]. Massachusetts Medical Society; 2018 [cited 2019 Jun 21];379:2220–9. Available from: http://www.nejm.org/doi/10.1056/NEJMoa1809064
249. Zhu AX, Finn RS, Edeline J, Cattan S, Ogasawara S, Palmer D, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol [Internet]. 2018 [cited 2019 Jun 21];19:940–52. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1470204518303516
250. Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D, et al. Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med [Internet]. 2019;NEJMoa1816714. Available from: http://www.nejm.org/doi/10.1056/NEJMoa181671

References 251-300

251. Motzer RJ, Penkov K, Haanen J, Rini B, Albiges L, Campbell MT, et al. Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med [Internet]. 2019 [cited 2019 Jun 21];380:1103–15. Available from: http://www.ncbi.nlm.nih.gov/pubmed/3077953
252. June CH, Warshauer JT, Bluestone JA. Is autoimmunity the Achilles’ heel of cancer immunotherapy? Nat Med [Internet]. 2017 [cited 2019 Jun 21];23:540–7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/2847557
253. Young A, Quandt Z, Bluestone JA. The Balancing Act between Cancer Immunity and Autoimmunity in Response to Immunotherapy. Cancer Immunol Res [Internet]. American Association for Cancer Research; 2018 [cited 2019 Jun 21];6:1445–52. Available from: http://cancerimmunolres.aacrjournals.org/lookup/doi/10.1158/2326-6066.CIR-18-0487
254. Kim YH, Bagot M, Pinter-Brown L, Rook AH, Porcu P, Horwitz SM, et al. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. Lancet Oncol [Internet]. Elsevier; 2018 [cited 2019 Jun 21];19:1192–204. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30100375
255. Leonard JP, Trneny M, Izutsu K, Fowler NH, Hong X, Zhu J, et al. AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma. J Clin Oncol [Internet]. 2019 [cited 2019 Jun 21];37:1188–99. Available from: https://ascopubs.org/doi/10.1200/JCO.19.00010
256. Centers for Disease Control and Prevention. Cancer Survivorship—United States, 1971–2001. Morbitity Mortal Wkly Rep. 2004;53:526–529.
257. Ekwueme DU, Zhao J, Rim SH, Moor JS De, Zheng Z, Khushalani JS, et al. Annual Out-of-Pocket Expenditures and Financial Hardship Among Cancer Survivors Aged 18 – 64 Years — United States , 2011 – 2016. 2019;68:2011–6.
258. Kwan ML, Yao S, Lee VS, Roh JM, Zhu Q, Ergas IJ, et al. Race/ethnicity, genetic ancestry, and breast cancer-related lymphedema in the Pathways Study. Breast Cancer Res Treat. Netherlands; 2016;159:119–29.
259. Keegan THM, Li Q, Steele A, Alvarez EM, Brunson A, Flowers CR, et al. Sociodemographic disparities in the occurrence of medical conditions among adolescent and young adult Hodgkin lymphoma survivors. Cancer Causes Control. Netherlands; 2018;29:551–61.
260. Litvak A, Batukbhai B, Russell SD, Tsai H-L, Rosner GL, Jeter SC, et al. Racial disparities in the rate of cardiotoxicity of HER2-targeted therapies among women with early breast cancer. Cancer [Internet]. 2018 [cited 2019 Jun 19];124:1904–11. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29381193
261. Andrykowski MA, Aarts MJ, van de Poll-Franse L V., Mols F, Slooter GD, Thong MSY. Low socioeconomic status and mental health outcomes in colorectal cancer survivors: disadvantage, advantage, … or both? Psychooncology [Internet]. 2013 [cited 2019 Jun 19];22:2462–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23712928
262. Weaver KE, Geiger AM, Lu L, Case LD. Rural-urban disparities in health status among US cancer survivors. Cancer [Internet]. John Wiley & Sons, Ltd; 2013 [cited 2019 Jul 16];119:1050–7. Available from: http://doi.wiley.com/10.1002/cncr.27840
263. Financial Toxicity and Cancer Treatment (PDQ®)—Health Professional Version – National Cancer Institute [Internet]. [cited 2019 Jun 20]. Available from: https://www.cancer.gov/about-cancer/managing-care/track-care-costs/financial-toxicity-hp-pdq
264. Gery B, Jr PG, Yabroff KR, Ekwueme DU, Smith AW, Dowling EC, et al. Estimating The Health And Economic Burden Of Cancer Among Those Diagnosed As Adolescents And Young Adults. 2014;1024–31.
265. Ketterl TG, Syrjala KL, Casillas J, Jacobs LA, Palmer SC, McCabe MS, et al. Lasting effects of cancer and its treatment on employment and finances in adolescent and young adult cancer survivors. Cancer [Internet]. 2019 [cited 2019 Jun 20];125:1908–17. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30707763
266. Barile JP, Reeve BB, Smith AW, Zack MM, Mitchell SA, Kobau R, et al. Monitoring population health for Healthy People 2020: evaluation of the NIH PROMIS® Global Health, CDC Healthy Days, and satisfaction with life instruments. Qual Life Res [Internet]. 2013 [cited 2019 Jun 20];22:1201–11. Available from: http://link.springer.com/10.1007/s11136-012-0246-z
267. Shapiro CL. Cancer Survivorship. Longo DL, editor. N Engl J Med [Internet]. 2018 [cited 2019 Jun 20];379:2438–50. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30575480
268. Armstrong GT, Chen Y, Yasui Y, Leisenring W, Gibson TM, Mertens AC, et al. Reduction in Late Mortality among 5-Year Survivors of Childhood Cancer. N Engl J Med [Internet]. NIH Public Access; 2016 [cited 2019 Jun 20];374:833–42. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26761625
269. Weaver KE, Forsythe LP, Reeve BB, Alfano CM, Rodriguez JL, Sabatino SA, et al. Mental and physical health-related quality of life among U.S. cancer survivors: population estimates from the 2010 National Health Interview Survey. Cancer Epidemiol Biomarkers Prev [Internet]. NIH Public Access; 2012 [cited 2019 Jun 20];21:2108–17. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23112268
270. Reeve BB, Potosky AL, Smith AW, Han PK, Hays RD, Davis WW, et al. Impact of Cancer on Health-Related Quality of Life of Older Americans. JNCI J Natl Cancer Inst [Internet]. 2009 [cited 2019 Jun 20];101:860–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19509357
271. Hoerger M, Wayser GR, Schwing G, Suzuki A, Perry LM. Impact of Interdisciplinary Outpatient Specialty Palliative Care on Survival and Quality of Life in Adults With Advanced Cancer: A Meta-Analysis of Randomized Controlled Trials. Ann Behav Med [Internet]. 2019 [cited 2019 Jun 20];53:674–85. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30265282
272. Basch E, Deal AM, Dueck AC, Scher HI, Kris MG, Hudis C, et al. Overall Survival Results of a Trial Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer Treatment. JAMA [Internet]. American Medical Association; 2017 [cited 2019 Jun 20];318:197–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28586821
273. Courneya KS, Mackey JR, Bell GJ, Jones LW, Field CJ, Fairey AS. Randomized Controlled Trial of Exercise Training in Postmenopausal Breast Cancer Survivors: Cardiopulmonary and Quality of Life Outcomes. J Clin Oncol [Internet]. 2003 [cited 2019 Jun 20];21:1660–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12721239
274. McTiernan A, Friedenreich CM, Katzmarzyk PT, Powell KE, Macko R, Buchner D, et al. Physical Activity in Cancer Prevention and Survival. Med Sci Sport Exerc [Internet]. 2019 [cited 2019 Jun 20];51:1252–61. Available from: http://www.ncbi.nlm.nih.gov/pubmed/31095082
275. Nguyen Q-N, Chun SG, Chow E, Komaki R, Liao Z, Zacharia R, et al. Single-Fraction Stereotactic vs Conventional Multifraction Radiotherapy for Pain Relief in Patients With Predominantly Nonspine Bone Metastases. JAMA Oncol [Internet]. 2019 [cited 2019 Jun 20];5:872. Available from: http://www.ncbi.nlm.nih.gov/pubmed/31021390
276. El-Jawahri A, Traeger L, Greer JA, VanDusen H, Fishman SR, LeBlanc TW, et al. Effect of Inpatient Palliative Care During Hematopoietic Stem-Cell Transplant on  Psychological Distress 6 Months After Transplant: Results of a Randomized Clinical Trial. J Clin Oncol. United States; 2017;35:3714–21.
277. Greer JA, Jacobs JM, El-Jawahri A, Nipp RD, Gallagher ER, Pirl WF, et al. Role of Patient Coping Strategies in Understanding the Effects of Early Palliative Care on Quality of Life and Mood. J Clin Oncol. United States; 2018;36:53–60.
278. May P, Normand C, Cassel J, al  et. Economics of palliative care for hospitalized adults with serious illness: A meta-analysis. JAMA Intern Med [Internet]. 2018;178:820–9. Available from: http://dx.doi.org/10.1001/jamainternmed.2018.0750
279. Medicine NA of. Dying in America: Improving Quality and Honoring Individual Preferences Near the End of Life [Internet]. 2014. Available from: http://www.nationalacademies.org/hmd/Reports/2014/Dying-In-America-Improving-Quality-and-Honoring-Individual-Preferences-Near-the-End-of-Life.aspx
280. Compton-phillips A, St P, Health J, Mohta NS, Catalyst N. Care Redesign Survey The Power of Palliative Care. 2019
281. Arrieta O, Angulo LP, Nunez-Valencia C, Dorantes-Gallareta Y, Macedo EO, Martinez-Lopez D, et al. Association of depression and anxiety on quality of life, treatment adherence, and prognosis in patients with advanced non-small cell lung cancer. Ann Surg Oncol. United States; 2013;20:1941–8.
282. Brown KW, Levy AR, Rosberger Z, Edgar L. Psychological distress and cancer survival: a follow-up 10 years after diagnosis. Psychosom Med. United States; 2003;65:636–43.
283. Rodin G, Lo C, Rydall A, Shnall J, Malfitano C, Chiu A, et al. Managing Cancer and Living Meaningfully (CALM): A randomized controlled trial of a psychological intervention for patients with advanced cancer. J Clin Oncol. 2018;36:2422–32.
284. Butow PN, Turner J, Gilchrist J, Sharpe L, Smith A Ben, Fardell JE, et al. Randomized Trial of ConquerFear: A Novel, Theoretically Based Psychosocial Intervention for Fear of Cancer Recurrence. J Clin Oncol. United States; 2017;35:4066–77.
285. Numbers E, Survivors C. Cancer Treatment & Survivorship. 2019;
286. Blanchard CM, Courneya KS, Stein K, American Cancer Society’s SCS-II. Cancer Survivors’ Adherence to Lifestyle Behavior Recommendations and Associations With Health-Related Quality of Life: Results From the American Cancer Society’s SCS-II. J Clin Oncol [Internet]. 2008 [cited 2019 Jun 20];26:2198–204. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18445845
287. Zhang FF, Hudson MM, Huang I-C, Bhakta N, Ness KK, Brinkman TM, et al. Lifestyle factors and health-related quality of life in adult survivors of childhood cancer: A report from the St. Jude Lifetime Cohort Study. Cancer [Internet]. John Wiley & Sons, Ltd; 2018 [cited 2019 Jun 20];124:3918–23. Available from: http://doi.wiley.com/10.1002/cncr.31647
288. Westmaas JL, Alcaraz KI, Berg CJ, Stein KD. Prevalence and Correlates of Smoking and Cessation-Related Behavior among Survivors of Ten Cancers: Findings from a Nationwide Survey Nine Years after Diagnosis. Cancer Epidemiol Biomarkers & Prev [Internet]. 2014;23:1783 LP – 1792. Available from: http://cebp.aacrjournals.org/content/23/9/1783.abstract
289. Toll BA, Brandon TH, Gritz ER, Warren GW, Herbst RS. Assessing tobacco use by cancer patients and facilitating cessation: an American  Association for Cancer Research policy statement. Clin Cancer Res. United States; 2013;19:1941–8.
290. EL VB, CS F, Niedzwiecki D, al  et. Association of survival with adherence to the american cancer society nutrition and physical activity guidelines for cancer survivors after colon cancer diagnosis: The calgb 89803/alliance trial. JAMA Oncol [Internet]. 2018; Available from: http://dx.doi.org/10.1001/jamaoncol.2018.0126
291. Song M, Wu K, Meyerhardt JA, Ogino S, Wang M, Fuchs CS, et al. Fiber Intake and Survival After Colorectal Cancer Diagnosis. JAMA Oncol. United States; 2018;4:71–9.
292. Friedenreich CM, Neilson HK, Farris MS, Courneya KS. Physical Activity and Cancer Outcomes: A Precision Medicine Approach. Clin Cancer Res. United States; 2016;22:4766–75.
293. Scott JM, Li N, Liu Q, Yasui Y, Leisenring W, Nathan PC, et al. Association of Exercise With Mortality in Adult Survivors of Childhood Cancer. JAMA Oncol [Internet]. 2018 [cited 2018 Jun 8]; Available from: http://oncology.jamanetwork.com/article.aspx?doi=10.1001/jamaoncol.2018.2254
294. Mishra SI, Scherer RW, Geigle PM, Berlanstein DR, Topaloglu O, Gotay CC, et al. Exercise interventions on health-related quality of life for cancer survivors. Cochrane Database Syst Rev [Internet]. 2012 [cited 2019 Jun 20];CD007566. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22895961
295. Mishra SI, Scherer RW, Snyder C, Geigle P, Gotay C. The Effectiveness of Exercise Interventions for Improving Health-Related Quality of Life From Diagnosis Through Active Cancer Treatment. Oncol Nurs Forum [Internet]. 2015 [cited 2019 Jun 20];42:E33–53. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25542333
296. Mustian KM, Alfano CM, Heckler C, Kleckner AS, Kleckner IR, Leach CR, et al. Comparison of Pharmaceutical, Psychological, and Exercise Treatments for Cancer-Related Fatigue. JAMA Oncol [Internet]. 2017 [cited 2019 Jun 20];3:961. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28253393
297. Craft LL, VanIterson EH, Helenowski IB, Rademaker AW, Courneya KS. Exercise Effects on Depressive Symptoms in Cancer Survivors: A Systematic Review and Meta-Analysis. Cancer Epidemiol Biomarkers Prev [Internet]. NIH Public Access; 2012 [cited 2019 Jun 20];21:3. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3253916/
298. Rogers LQ, Courneya KS, Oster RA, Anton, PM, Robbs RS, Forero A, et al. Physical Activity and Sleep Quality in Breast Cancer Survivors. Med Sci Sport Exerc [Internet]. 2017 [cited 2019 Jun 20];49:2009–15. Available from: http://insights.ovid.com/crossref?an=00005768-201710000-00006
299. Irwin ML, Cartmel B, Gross CP, Ercolano E, Li F, Yao X, et al. Randomized Exercise Trial of Aromatase Inhibitor–Induced Arthralgia in Breast Cancer Survivors. J Clin Oncol [Internet]. American Society of Clinical Oncology; 2015 [cited 2019 Jun 20];33:1104. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4372849/
300. Kleckner IR, Kamen C, Gewandter JS, Mohile NA, Heckler CE, Culakova E, et al. Effects of exercise during chemotherapy on chemotherapy-induced peripheral neuropathy: A multicenter, randomized controlled trial. Support Care Cancer [Internet]. 2018 [cited 2019 Jun 20];26:1019–28. Available from: http://link.springer.com/10.1007/s00520-017-4013-0

References 301-345

301. Loh KP, Kleckner IR, Lin P, Mohile SG, Canin BE, Flannery MA, et al. Effects of a Home‐based Exercise Program on Anxiety and Mood Disturbances in Older Adults with Cancer Receiving Chemotherapy. J Am Geriatr Soc [Internet]. 2019 [cited 2019 Jun 20];67:1005–11. Available from: http://www.ncbi.nlm.nih.gov/pubmed/31034591
302. Schmitz KH, Ahmed RL, Troxel AB, Cheville A, Lewis-Grant L, Smith R, et al. Weight Lifting for Women at Risk for Breast Cancer–Related Lymphedema. JAMA [Internet]. American Medical Association; 2010 [cited 2019 Jun 20];304:2699. Available from: http://jama.jamanetwork.com/article.aspx?doi=10.1001/jama.2010.1837
303. Northey JM, Cherbuin N, Pumpa KL, Smee DJ, Rattray B. Exercise interventions for cognitive function in adults older than 50: A systematic review with meta-analysis. Br J Sports Med [Internet]. BMJ Publishing Group Ltd and British Association of Sport and Exercise Medicine; 2018 [cited 2019 Jun 20];52:154–60. Available from: https://bjsm.bmj.com/content/52/3/154
304. Scott JM, Zabor EC, Schwitzer E, Koelwyn GJ, Adams SC, Nilsen TS, et al. Efficacy of Exercise Therapy on Cardiorespiratory Fitness in Patients With Cancer: A Systematic Review and Meta-Analysis. J Clin Oncol [Internet]. 2018 [cited 2019 Jun 20];36:2297–305. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29894274
305. Rock CL, Doyle C, Demark-Wahnefried W, Meyerhardt J, Courneya KS, Schwartz AL, et al. Nutrition and physical activity guidelines for cancer survivors. CA Cancer J Clin [Internet]. American Cancer Society; 2012 [cited 2019 Jun 20];62:242–74. Available from: http://doi.wiley.com/10.3322/caac.21142
306. Cheville AL, Mustian K, Winters-Stone K, Zucker DS, Gamble GL, Alfano CM. Cancer Rehabilitation. Phys Med Rehabil Clin N Am [Internet]. 2017 [cited 2019 Jun 20];28:1–17. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27912990
307. Silver JK, Baima J, Mayer RS. Impairment-driven cancer rehabilitation: An essential component of quality care and survivorship. CA Cancer J Clin [Internet]. 2013 [cited 2019 Jun 20];63:295–317. Available from: http://doi.wiley.com/10.3322/caac.21186
308. Silver JK. Cancer Prehabilitation and its Role in Improving Health Outcomes and Reducing Health Care Costs. Semin Oncol Nurs [Internet]. 2015 [cited 2019 Jun 20];31:13–30. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25636392
309. Tippett DC, Webster KT. Rehabilitation Needs of Patients with Oropharyngeal Cancer. Otolaryngol Clin North Am [Internet]. 2012 [cited 2019 Jun 20];45:863–78. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22793857
310. Santa Mina D, Hilton WJ, Matthew AG, Awasthi R, Bousquet-Dion G, Alibhai SMH, et al. Prehabilitation for radical prostatectomy: A multicentre randomized controlled trial. Surg Oncol [Internet]. 2018 [cited 2019 Jul 17];27:289–98. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0960740418300987
311. Yang A, Sokolof J, Gulati A. The effect of preoperative exercise on upper extremity recovery following breast cancer surgery. Int J Rehabil Res [Internet]. 2018 [cited 2019 Jul 15];41:189–96. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29683834
312. Cheville AL, Moynihan T, Herrin J, Loprinzi C, Kroenke K. Effect of Collaborative Telerehabilitation on Functional Impairment and Pain among Patients with Advanced-Stage Cancer: A Randomized Clinical Trial. JAMA Oncol. 2019;5:644–52.
313. Implementation Science at a Glance.
314. Zhao Y, Brettle A, Qiu L. The Effectiveness of Shared Care in Cancer Survivors—A Systematic Review. Int J Integr Care [Internet]. 2018 [cited 2019 Jul 29];18:2. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30483035
315. Alfano CM, Mayer DK, Bhatia S, Maher J, Scott JM, Nekhlyudov L, et al. Implementing personalized pathways for cancer follow‐up care in the United States: Proceedings from an American Cancer Society–American Society of Clinical Oncology summit. CA Cancer J Clin [Internet]. American Cancer Society; 2019 [cited 2019 Jul 29];69:234–47. Available from: https://onlinelibrary.wiley.com/doi/abs/10.3322/caac.21558
316. Kent EE, Dionne-Odom JN. Population-Based Profile of Mental Health and Support Service Need Among Family Caregivers of Adults With Cancer. J Oncol Pract [Internet]. American Society of Clinical Oncology; 2019 [cited 2019 Jun 20];15:e122–31. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30496020
317. Feature T. Cellular census to guide cancer care. :8–10. Available from: https://doi. 
318. The Human Tumor Atlas Network Creates New Cancer Maps – National Cancer Institute [Internet]. [cited 2019 Jun 20]. Available from: https://www.cancer.gov/news-events/cancer-currents-blog/2019/human-tumor-atlas-network-cancer-maps?cid=eb_govdel
319. Wright AV, Nuñez JK, Doudna JA. Biology and Applications of CRISPR Systems: Harnessing Nature’s Toolbox for Genome Engineering. Cell [Internet]. 2016 [cited 2018 Jun 18];164:29–44. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26771484
320. Bhaya D, Davison M, Barrangou R. CRISPR-Cas Systems in Bacteria and Archaea: Versatile Small RNAs for Adaptive Defense and Regulation. Annu Rev Genet [Internet]. 2011 [cited 2019 Jun 20];45:273–97. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22060043
321. Mollanoori H, Shahraki H, Rahmati Y, Teimourian S. CRISPR/Cas9 and CAR-T cell, collaboration of two revolutionary technologies in cancer immunotherapy, an instruction for successful cancer treatment. Hum Immunol [Internet]. 2018 [cited 2019 Jun 20];79:876–82. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30261221
322. Merker JD, Oxnard GR, Compton C, Diehn M, Hurley P, Lazar AJ, et al. Circulating Tumor DNA Analysis in Patients With Cancer : American Society of Clinical Oncology and College of American Pathologists Joint Review. 2019;36.
323. Shen SY, Singhania R, Fehringer G, Chakravarthy A, Roehrl MHA, Chadwick D, et al. Sensitive tumour detection and classification using plasma cell-free DNA methylomes. Nature [Internet]. Nature Publishing Group; 2018 [cited 2019 Jun 3];563:579–83. Available from: http://www.nature.com/articles/s41586-018-0703-0
324. Cristiano S, Leal A, Phallen J, Fiksel J, Adleff V, Bruhm DC, et al. Genome-wide cell-free DNA fragmentation in patients with cancer. Nature [Internet]. 2019 [cited 2019 Jun 20];570:385–9. Available from: http://www.nature.com/articles/s41586-019-1272-6
325. Panditharatna E, Kilburn LB, Aboian MS, Kambhampati M, Gordish-Dressman H, Magge SN, et al. Clinically Relevant and Minimally Invasive Tumor Surveillance of Pediatric Diffuse Midline Gliomas Using Patient-Derived Liquid Biopsy. Clin Cancer Res [Internet]. 2018 [cited 2019 Jun 20];24:5850–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30322880
326. Li BT, Janku F, Jung B, Hou C, Madwani K, Alden R, et al. Ultra-deep next-generation sequencing of plasma cell-free DNA in patients with advanced lung cancers : Results from the Actionable Genome Consortium. 2019;1–7.
327. Wang D-S, Liu Z-X, Lu Y-X, Bao H, Wu X, Zeng Z-L, et al. Liquid biopsies to track trastuzumab resistance in metastatic HER2-positive gastric cancer. Gut [Internet]. 2019 [cited 2019 Jun 20];68:1152–61. Available from: http://gut.bmj.com/lookup/doi/10.1136/gutjnl-2018-316522
328. Leighl NB, Page RD, Raymond VM, Daniel DB, Divers SG, Reckamp KL, et al. Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non-small Cell Lung Cancer. Clin Cancer Res [Internet]. American Association for Cancer Research; 2019 [cited 2019 Jun 20]; Available from: http://www.ncbi.nlm.nih.gov/pubmed/30988079
329. The Clinical Cancer Genome Task Team of the Global Alliance for Genomics and Health. Sharing Clinical and Genomic Data on Cancer — The Need for Global Solutions. N Engl J Med [Internet]. 2017;376:2004–6. Available from: http://www.nejm.org/doi/10.1056/NEJMp1700601
330. Topol EJ. High-performance medicine: The convergence of human and artificial intelligence. Nat Med [Internet]. Springer US; 2019;25:44–56. Available from: http://www.nature.com/articles/s41591-018-0300-7
331. Ardila D, Kiraly AP, Bharadwaj S, Choi B, Reicher JJ, Peng L, et al. End-to-end lung cancer screening with three-dimensional deep learning on low-dose chest computed tomography. Nat Med [Internet]. Nature Publishing Group; 2019 [cited 2019 Jun 20];25:954–61. Available from: http://www.nature.com/articles/s41591-019-0447-x
332. Raghu VK, Zhao W, Pu J, Leader JK, Wang R, Herman J, et al. Feasibility of lung cancer prediction from low-dose CT scan and smoking factors using causal models. Thorax [Internet]. BMJ Publishing Group Ltd; 2019 [cited 2019 Jun 20];74:643–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30862725
333. Hu L, Bell D, Antani S, Xue Z, Yu K, Horning MP, et al. An Observational Study of Deep Learning and Automated Evaluation of Cervical Images for Cancer Screening. JNCI J Natl Cancer Inst [Internet]. 2019 [cited 2019 Jun 20]; Available from: https://academic.oup.com/jnci/advance-article/doi/10.1093/jnci/djy225/5272614
334. Mori Y, Kudo S, Misawa M, Saito Y, Ikematsu H, Hotta K, et al. Real-Time Use of Artificial Intelligence in Identification of Diminutive Polyps During Colonoscopy. Ann Intern Med [Internet]. American College of Physicians; 2018 [cited 2019 Jun 20];169:357. Available from: http://annals.org/article.aspx?doi=10.7326/M18-0249
335. Dicker AP, Jim HSL. Intersection of Digital Health and Oncology. JCO Clin Cancer Informatics. 2018;1–4.
336. Garg S, Williams NL, Ip A, Dicker AP. Clinical Integration of Digital Solutions in Health Care: An Overview of the Current Landscape of Digital Technologies in Cancer Care. JCO Clin Cancer Informatics. 2018;1–9.
337. Basch E. Patient-Reported Outcomes — Harnessing Patients’ Voices to Improve Clinical Care. Nejm [Internet]. 2016;1–3. Available from: http://scholar.google.com/scholar?hl=en&btnG=Search&q=intitle:New+engla+nd+journal#0
338. Denis F, Lethrosne C, Pourel N, Molinier O, Pointreau Y, Domont J, et al. Randomized Trial Comparing a Web-Mediated Follow-up With Routine Surveillance in Lung Cancer Patients. JNCI J Natl Cancer Inst [Internet]. Narnia; 2017 [cited 2019 Jul 15];109. Available from: https://academic.oup.com/jnci/article/doi/10.1093/jnci/djx029/3573360
339. Harrington KJ. Ultrahigh Dose-rate Radiotherapy: Next Steps for FLASH-RT. Clin Cancer Res [Internet]. 2019 [cited 2019 Jun 20];25:3–5. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30093447
340. Lempart M, Blad B, Adrian G, Bäck S, Knöös T, Ceberg C, et al. Modifying a clinical linear accelerator for delivery of ultra-high dose rate irradiation. Radiother Oncol [Internet]. 2019 [cited 2019 Jun 20]; Available from: http://www.ncbi.nlm.nih.gov/pubmed/30755324
341. Vozenin M-C, De Fornel P, Petersson K, Favaudon V, Jaccard M, Germond J-F, et al. The Advantage of FLASH Radiotherapy Confirmed in Mini-pig and Cat-cancer Patients. Clin Cancer Res [Internet]. 2019 [cited 2019 Jun 20];25:35–42. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29875213
342. NIH’s Role in Sustaining the U . S . Economy. 2012
343. de Martel C, Plummer M, Vignat J, Franceschi S. Worldwide burden of cancer attributable to HPV by site, country and HPV type. Int J cancer [Internet]. Wiley-Blackwell; 2017 [cited 2019 Jun 20];141:664–70. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28369882
344. Cigarette Smoking Among Adults — United States, 1990 [Internet]. [cited 2019 Aug 2]. Available from: https://www.cdc.gov/mmwr/preview/mmwrhtml/00016738.htm
345. Facts C. Cancer Facts & Figures 2018. 2018;